BioCentury
ARTICLE | Company News

Incyte sales and marketing update

February 17, 2017 4:46 PM UTC

The U.K.'s NICE issued draft guidance recommending the use of Iclusig ponatinib from Incyte in specific patients with chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

NICE recommends treatment in adult chronic CML patients who have the T315I mutation; in accelerated or blast phase CML patients who are resistant to or unable to take Sprycel dasatinib or Tasigna nilotinib and for whom Gleevec imatinib is not appropriate; and in patients who have the T315I mutation. In patients with ALL, Iclusig is recommended for adults whose disease is resistant to Sprycel, in patients that cannot take Sprycel or Gleevec, and when the T315I mutation is present. The recommendation is contingent on Incyte providing the drug for both indications at an undisclosed discount...

BCIQ Company Profiles

Incyte Corp.